Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs

OBJECTIVE: To investigate the risk of developing lower intestinal perforations (LIPs) in patients with rheumatoid arthritis (RA) treated with tocilizumab (TCZ). METHODS: In 13 310 patients with RA observed in the German biologics register Rheumatoid Arthritis: Observation of Biologic Therapy, 141 se...

Descripción completa

Detalles Bibliográficos
Autores principales: Strangfeld, A, Richter, A, Siegmund, B, Herzer, P, Rockwitz, K, Demary, W, Aringer, M, Meißner, Y, Zink, A, Listing, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445993/
https://www.ncbi.nlm.nih.gov/pubmed/27405509
http://dx.doi.org/10.1136/annrheumdis-2016-209773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445993/
https://www.ncbi.nlm.nih.gov/pubmed/27405509
http://dx.doi.org/10.1136/annrheumdis-2016-209773

Ejemplares similares